HPGC(SH:600664)2015-10-30 16:00Financial Performance - Operating revenue for the year-to-date was CNY 12,538,947,714.83, down 3.62% from CNY 13,009,901,380.84 in the same period last year[7] - Net profit attributable to shareholders was CNY 402,468,748.52, an increase of 23.61% compared to CNY 325,608,343.33 in the previous year[7] - Basic earnings per share rose to CNY 0.2099, reflecting a growth of 23.62% from CNY 0.1698[7] - Total revenue for Q3 2015 was CNY 3,397,769,025.02, a decrease of 14.6% compared to CNY 3,981,594,167.14 in Q3 2014[28] - Total operating revenue for Q3 2015 was CNY 588,618,103.24, a decrease of 52.7% compared to CNY 1,242,135,477.25 in the same period last year[32] - Net profit for Q3 2015 was CNY 37,621,519.76, compared to a net loss of CNY 2,414,216.88 in Q3 2014[30] - Total profit for Q3 2015 reached CNY 46,639,222.79, significantly higher than CNY 15,426,541.83 in Q3 2014[30] - The company reported a total comprehensive income for Q3 2015 of CNY 37,621,519.76, compared to a loss of CNY 2,414,216.88 in Q3 2014[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 15,632,885,320.11, a decrease of 3.76% compared to the end of the previous year[7] - Total liabilities increased to CNY 8,344,427,325.27 from CNY 7,473,005,427.66, representing an increase of 11.6%[22] - Current liabilities totaled CNY 7,635,847,436.43, up from CNY 6,750,644,875.68, marking an increase of 13.1%[22] - The company's equity attributable to shareholders decreased to CNY 6,723,150,611.46 from CNY 8,238,165,151.94, a decline of 18.4%[22] - Cash and cash equivalents rose to CNY 2,438,655,055.76 from CNY 1,686,003,544.97, reflecting a growth of 44.5%[24] - Accounts receivable increased to CNY 583,501,671.15 from CNY 948,239,282.76, a decline of 38.6%[24] - Inventory decreased to CNY 1,004,561,022.87 from CNY 1,463,363,775.73, showing a reduction of 31.3%[25] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 767,818,991.61, a decrease of 23.60% compared to CNY 1,005,019,794.71 in the same period last year[7] - Cash flow from financing activities showed a net outflow of ¥29.34 million, a significant decrease compared to the previous year[11] - The net cash flow from operating activities for the first nine months of 2015 was 767,818,991.61 RMB, compared to 1,005,019,794.71 RMB in the previous year, a decrease of about 23.6%[36] - Cash and cash equivalents at the end of Q3 2015 totaled 2,919,896,953.63 RMB, an increase from 2,411,099,296.39 RMB at the end of the same period last year[37] - Cash flow from financing activities showed a net inflow of $17,913,944.04, reversing from a net outflow of $61,338,516.45 in the previous year[41] Shareholder Information - The total number of shareholders at the end of the reporting period was 74,305[9] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., held 902,441,450 shares, representing 47.06% of the total shares[9] - A cash dividend of ¥10 per 10 shares was approved, totaling ¥1,917.48 million based on the total share capital as of June 30, 2015[12] - The company reported a 37.44% decrease in undistributed profits to ¥2,530.99 million due to the declaration of cash dividends[11] Expenses and Costs - Sales expenses decreased by 40.49% to ¥1,185.26 million due to adjustments in marketing strategies and reduced advertising costs[11] - The company incurred operating expenses of 10,352,984,648.63 RMB in the first nine months of 2015, compared to 10,945,100,480.82 RMB in the same period last year, indicating a reduction in expenses[36] - The financial expenses for Q3 2015 were reported as CNY -10,684,157.10, indicating a slight improvement from CNY -11,287,773.11 in Q3 2014[32] Investment Activities - Investment activities resulted in a net cash outflow of -211,716,312.69 RMB for the first nine months of 2015, compared to -262,244,282.61 RMB in the previous year[36] - The company recorded investment income of CNY 80,929.57 in Q3 2015, compared to a loss of CNY 547,108.89 in the same quarter last year[32]